Show simple item record

dc.contributor.authorWalimbwa, Stephen Ian
dc.contributor.authorKaboggoza, Julian Paul
dc.contributor.authorWaitt, Catriona
dc.contributor.authorByakika-Kibwika, Pauline
dc.contributor.authorD'Avolio, Antonio
dc.contributor.authorLamorde, Mohammed
dc.date.accessioned2022-01-12T07:53:39Z
dc.date.available2022-01-12T07:53:39Z
dc.date.issued2021
dc.identifier.citationWalimbwa, S. I., Kaboggoza, J. P., Waitt, C., Byakika-Kibwika, P., D'Avolio, A., & Lamorde, M. (2021). An open-label, randomized, single intravenous dosing study to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). https://orcid.org/0000-0002-3825-3260en_US
dc.identifier.urihttps://orcid.org/0000-0002-3825-3260
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1200
dc.description.abstractRemdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases. The purpose of this study is to explore how commonly utilized antiretroviral therapy (tenofovir disoproxil fumarate /lamivudine [TDF/3TC] and atazanavir/ritonavir [ATV/r]) influence plasma and intracellular concentrations of remdesivir.en_US
dc.language.isoenen_US
dc.publisherResearch Squareen_US
dc.subjectRemdesiviren_US
dc.subjectCOVID-19en_US
dc.subjectEbolaen_US
dc.subjectHIVen_US
dc.subjectAtazanaviren_US
dc.subjectRitonaviren_US
dc.subjectTenofoviren_US
dc.subjectLamivudineen_US
dc.subjectDrug-drug interactionsen_US
dc.titleAn open-label, randomized, single intravenous dosing study to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)en_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record